Introduction
Begin and associates first reported lymphoepithelioma-like carcinoma (LELC) in 1987 [1] .
More than 150 cases were reported until 2006 [2] . The commonest site of primary tumour is the lung but LELC has also been reported in salivary glands, thymus, stomach, urogenital system and skin. LELC is closely associated with Epstein-Barr virus (EBV) infection and mostly seen in Asia with nearly two-thirds of the reported cases found in Taiwan, Southern China, and Hong Kong [3] .
On histology, LELC is similar to undifferentiated nasopharyngeal carcinoma (NPC). The tumour cells are arranged in nests or sheets with intense lymphoplasmacytic cell infiltration.
The cell borders are ill-defined, giving rise to syncytial aggregation of tumour cells. The cell nuclei are round, oval, or elongated, with mildly irregular nuclear borders, clumped chromatin, and 1 or 2 distinct eosinophilic nucleoli. Association with EBV is observed mainly in LELC arising in the Asian population, which can be demonstrated by serologic, immunohistochemical, nucleic acid detection and in-situ hybridization techniques. In-situ hybridization using a sensitive digoxigenin-labelled RNA probe is the most commonly employed detection method for EBV-encoded small RNAs (EBER) [4] . Patchy expression of the viral latent membrane protein (LMP-1) can be demonstrated using immunohistochemistry [4] . In cancers that morphologically resemble LELC but which arise in Caucasians or in other organs such as skin, vagina and urinary bladder are not associated with EBV infection [3] .
The most common type of LELC, pulmonary LELC, accounts for 0.9% of bronchogenic carcinoma [5] . The prognosis of pulmonary LELC is better compared to other non-LELC lung carcinoma; the 2-year and 5-year overall survival rates for pulmonary LELC were reported as 79.9% and 53.5% as compared to non-LELC lung carcinoma, which were lower at 59.5% and 39.1% respectively [3] . It is also indistinguishable from the metastasis originated from NPC. Therefore, nasopharyngeal origin needs to be excluded in all cases.
According to WHO histological classification of lung tumours, pulmonary LELC belongs to a subtype of variants of large cell carcinoma [3] .
This article aimed to demonstrate the potential roles of 18 F-FDG PET/CT in the assessment of LELC from initial disease detection to surveillance; allowing global reflection of metabolic active tumour burden in assisting treatment stratification and clinical management. were performed for treatment response assessment (Fig. 3) . 18 FDG PET/CT helps to identify patient who experiences progressive disease, to spare the patient from ineffective treatment and to offer alternative therapy.
Methods

Seven
Detection of Recurrence
Tumour progression could occur after years of stable disease. A 65-year-old woman, with diagnosis of stage IV pulmonary LELC in 2007, was previously treated by radiotherapy to mediastinum, followed by 6 cycles of chemotherapy. She remained in remission until early 2010, when she complained of low back pain and pelvic pain. 18 FDG PET/CT was requested to detect disease recurrence (Fig. 4) . Disease surveillance is important; 18 F-FDG PET/CT helps to differentiate tumour recurrence from benign pathology, such as that of posttreatment changes and sometimes, infective entities.
Non-pulmonary LELC
Although pulmonary LELC is the most common type of LELC, it can affect other organs.
These non-pulmonary LELC, including the recurrences, are 18 FDG-avid in our experience.
We present a case of thymic LELC in a 53-year-old man with symptoms of superior vena cava obstruction. Staging 18 FDG PET/CT was performed (Fig. 5) .
Next, we present a 30-year-old man with limb numbness, weakness and muscle wasting; a clinical suspicion of myasthenia gravis was suspected. CT detected a huge anterior mediastinal mass with a left liver mass. Therefore, 18 FDG PET/CT was subsequently requested for disease evaluation (Fig. 6) . He underwent radical thymectomy, in which carcinoma of LELC variant was confirmed.
Finally, we present a 66-year-old man, who was previously treated for LELC of the parotid gland in 1997 with right parotidectomy and radiotherapy. In 2015, he represented with hepatomegaly and EBV DNA was elevated to 42375 copies/ml. 18 FDG PET/CT was performed to detect disease recurrence (Fig. 7) . (D) Nasal endoscopy reveals irregular mucosal corresponding to the left nasopharynx uptake.
Conclusion
Subsequent biopsy result was negative for malignancy, ruling out the presence of nasopharyngeal carcinoma. 
